Corvus Pharmaceuticals, Inc. Proceeds from Common Stock Issued
Corvus Pharmaceuticals, Inc. (CRVS) reported Proceeds from Common Stock Issued of $189.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $0.00.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $189.41M.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2024 was $16.41M.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2021 was $31.99M.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2018 was $64.88M, a 9024.75% increase from fiscal 2017.
- Corvus Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2017 was $711.00K, a 99.00% decline from fiscal 2016.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $189.41M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $189.41M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $16.41M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $16.41M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $16.41M 10-Q · filed 2025-08-07 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 derived: sum of 3 quarters · filed 2024-03-19 | $31.99M 10-K · filed 2024-03-19 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $31.99M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $31.99M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $31.99M 10-Q · filed 2022-05-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $0.00 derived: sum of 2 quarters · filed 2020-03-09 | $0.00 derived: sum of 3 quarters · filed 2020-03-09 | $64.88M 10-K · filed 2020-03-09 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $0.00 derived: sum of 2 quarters · filed 2019-10-29 | $64.88M 10-Q · filed 2019-10-29 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $64.88M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $64.88M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $711.00K 10-K · filed 2020-03-09 | |||
| 2016-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$1.00K derived: sum of 2 quarters · filed 2019-03-07 | $7.01M derived: sum of 3 quarters · filed 2019-03-07 | $71.35M 10-K · filed 2019-03-07 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $7.01M derived: sum of 2 quarters · filed 2017-11-02 | $71.36M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $7.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $71.36M 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $64.34M 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |